Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 139.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 78,686 shares of the company's stock after buying an additional 45,791 shares during the quarter. Envestnet Asset Management Inc.'s holdings in Hims & Hers Health were worth $1,903,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

HIMS traded up $2.84 during trading hours on Friday, reaching $39.00. 19,464,321 shares of the stock traded hands, compared to its average volume of 16,626,194. The firm's fifty day simple moving average is $32.19 and its two-hundred day simple moving average is $31.30. The company has a market cap of $8.66 billion, a price-to-earnings ratio of 88.77 and a beta of 1.65. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares in the company, valued at $230,441.46. The trade was a 21.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 50,000 shares of the firm's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $36.39, for a total transaction of $1,819,500.00. Following the completion of the transaction, the chief executive officer now owns 92,103 shares in the company, valued at approximately $3,351,628.17. The trade was a 35.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 666,234 shares of company stock valued at $26,387,645. Insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Leerink Partners raised their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Truist Financial lowered their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Citigroup cut their target price on Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating on the stock in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and a consensus target price of $36.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.